Flis Vojko, Potrc Stojan, Kobilica Nina, Ivanecz Arpad
Department of Vascular Surgery, Surgical clinics, University Clinical Centre Maribor, Slovenia.
Radiol Oncol. 2016 Jul 19;50(3):321-8. doi: 10.1515/raon-2015-0017. eCollection 2016 Sep 1.
Recent reports have shown that patients with vascular tumour invasion who undergo concurrent vascular resection can achieve long-term survival rates equivalent to those without vascular involvement requiring pancreaticoduodenectomy alone. There is no consensus about which patients benefit from the portal-superior mesenteric vein resection and there is no consensus about the best surgical technique of vessel reconstruction (resection with or without graft reconstruction). As published series are small the aim of this study was to evaluate our experience in pancreatectomies with en bloc vascular resection and reconstruction of vessels.
Review of database at University Clinical Centre Maribor identified 133 patients (average age 65.4 ± 8.6 years, 69 female patients) who underwent pancreatoduodenectomy between January 2006 and August 2014. Clinical data, operative results, pathological findings and postoperative outcomes were collected prospectively and analyzed. Current literature and our experience in pancreatectomies with en bloc vascular resection and reconstruction of portal vein are reviewed.
Twenty-two patients out of 133 (16.5%) had portal vein-superior mesenteric vein resection and portal vein reconstruction (PVR) during pancreaticoduodenectomy. In fourteen patients portal vein was reconstructed without the use of synthetic vascular graft. In these series two types of venous reconstruction were performed. When tumour involvement was limited to the superior mesenteric vein (SPV) or portal vein (PV) such that the splenic vein could be preserved, and vessels could be approximated without tension a primary end-to-end anastomosis was performed. When tumour involved the SMV-splenic vein confluence, splenic vein ligation was necessary. In the remaining eight procedures interposition graft was needed. Dacron grafts with 10 mm diameter were used. There was no infection after dacron grafting. One patient had portal vein thrombosis after surgery: it was thrombosis after primary reconstruction. There were no thromboses in patients with synthetic graft interposition. There were no significant differences in postoperative morbidity, mortality or grades of complication between groups of patients with or without a PVR. Median survival time in months was in a group with vein resection 16.13 months and in a group without vein resection 15.17 months. Five year survival in the group without vein resection was 19.5%. Comparison of survival curves showed equal hazard rates with log-rank p = 0.090.
Survival of patients with pancreatic cancer who undergo an R0 resection with reconstruction was comparable to those who have a standard pancreaticoduodenectomy with no added mortality or morbidity. Synthetic graft appeared to be an effective and safe option as an interposition graft for portomesenteric venous reconstruction after pancreaticoduodenectomy.
最近的报告显示,伴有血管肿瘤侵犯并同时接受血管切除的患者可获得与仅需行胰十二指肠切除术而无血管受累患者相当的长期生存率。对于哪些患者能从门静脉-肠系膜上静脉切除中获益尚无共识,并且对于血管重建的最佳手术技术(切除时是否使用移植物重建)也没有达成共识。由于已发表的系列研究样本量较小,本研究的目的是评估我们在整块血管切除及血管重建的胰腺切除术中的经验。
回顾马里博尔大学临床中心数据库,确定了2006年1月至2014年8月期间接受胰十二指肠切除术的133例患者(平均年龄65.4±8.6岁,女性患者69例)。前瞻性收集并分析临床数据、手术结果、病理发现及术后结局。回顾当前文献以及我们在整块血管切除及门静脉重建的胰腺切除术中的经验。
133例患者中有22例(16.5%)在胰十二指肠切除术中进行了门静脉-肠系膜上静脉切除及门静脉重建(PVR)。14例患者在未使用人工血管移植物的情况下进行了门静脉重建。在这些病例系列中进行了两种类型的静脉重建。当肿瘤侵犯局限于肠系膜上静脉(SMV)或门静脉(PV),且脾静脉可保留,血管能够无张力地对合时,进行端端吻合。当肿瘤累及SMV-脾静脉汇合处时,则需要结扎脾静脉。其余8例手术需要植入移植物。使用了直径为10mm的涤纶移植物。涤纶移植术后无感染发生。1例患者术后发生门静脉血栓形成:是初次重建后发生的血栓。植入人工移植物的患者未发生血栓形成。有或无PVR的患者组在术后发病率、死亡率或并发症分级方面无显著差异。行静脉切除组的中位生存时间为16.13个月,未行静脉切除组为15.17个月。未行静脉切除组的5年生存率为19.5%。生存曲线比较显示风险率相等,对数秩检验p = 0.090。
接受R0切除并重建的胰腺癌患者的生存率与接受标准胰十二指肠切除术的患者相当,且未增加死亡率或发病率。人工移植物似乎是胰十二指肠切除术后作为门肠系膜静脉重建植入移植物的一种有效且安全的选择。